47
Participants
Start Date
November 9, 2020
Primary Completion Date
March 15, 2024
Study Completion Date
August 19, 2025
Abemaciclib
Administered orally
Irinotecan
Administered IV
Temozolomide
Administered orally
Dinutuximab
Administered IV
GM-CSF
Administered SC
Fondazione Policlinico Universitario Agostino Gemelli, Rome
Perth Children's Hospital, Perth
Hospital Universitari Vall d'Hebron, Barcelona
UZ Gent, Ghent
Cohen Children's Medical Center, New Hyde Park
Charité Campus Virchow-Klinikum, Berlin
Children's Hospital of Philadelphia (CHOP), Philadelphia
Hospital Infantil Universitario Niño Jesús, Madrid
Atrium Health - Carolinas Medical Center, Charlotte
Universitaetsklinikum Essen, Essen
Cincinnati Children's Hospital Medical Center, Cincinnati
Hospital Universitari i Politecnic La Fe, Valencia
Riley Hospital for Children at Indiana University Health, Indianapolis
Spectrum Health, Grand Rapids
Universitaetsklinikum Heidelberg, Heidelberg
Institut Curie, Paris
Phoenix Children's Hospital, Phoenix
Kaiser Permanente Oakland, Oakland
Gustave Roussy, Villejuif
Kaiser Permanente Santa Clara, Santa Clara
Kaiser Permanente Roseville, Roseville
The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles
Lifespan Cancer Institute, Providence
Centre Leon Berard, Lyon
National Cancer Center Hospital, Chuo Ku
Eli Lilly and Company
INDUSTRY